NEOS Investment Management LLC Has $3.84 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

NEOS Investment Management LLC trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,323 shares of the biopharmaceutical company’s stock after selling 1,853 shares during the quarter. NEOS Investment Management LLC’s holdings in Alnylam Pharmaceuticals were worth $3,841,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sava Infond d.o.o. acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $407,000. Elo Mutual Pension Insurance Co raised its position in Alnylam Pharmaceuticals by 18.3% in the fourth quarter. Elo Mutual Pension Insurance Co now owns 13,208 shares of the biopharmaceutical company’s stock worth $3,108,000 after purchasing an additional 2,043 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Alnylam Pharmaceuticals by 11.0% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 94,698 shares of the biopharmaceutical company’s stock worth $22,186,000 after purchasing an additional 9,393 shares during the period. Zions Bancorporation N.A. boosted its holdings in Alnylam Pharmaceuticals by 13.5% during the fourth quarter. Zions Bancorporation N.A. now owns 672 shares of the biopharmaceutical company’s stock valued at $158,000 after purchasing an additional 80 shares in the last quarter. Finally, TD Asset Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 3.2% in the 4th quarter. TD Asset Management Inc. now owns 504,038 shares of the biopharmaceutical company’s stock valued at $118,605,000 after purchasing an additional 15,755 shares during the period. 92.97% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the transaction, the executive vice president now owns 14,321 shares of the company’s stock, valued at $3,654,862.41. This trade represents a 4.42 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Pushkal Garg sold 1,548 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at $3,017,271.63. The trade was a 11.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock valued at $19,958,097 over the last three months. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.7 %

ALNY opened at $271.02 on Friday. The firm has a 50 day simple moving average of $259.42 and a 200 day simple moving average of $260.39. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a market cap of $35.09 billion, a price-to-earnings ratio of -124.89 and a beta of 0.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $280.00 to $328.00 in a report on Monday. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Chardan Capital reiterated a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Finally, Wells Fargo & Company boosted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have given a buy rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $312.30.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.